WO2007097286A1 - 痒み並びに炎症を抑制・緩和するための薬剤及び機能性食品 - Google Patents
痒み並びに炎症を抑制・緩和するための薬剤及び機能性食品 Download PDFInfo
- Publication number
- WO2007097286A1 WO2007097286A1 PCT/JP2007/052978 JP2007052978W WO2007097286A1 WO 2007097286 A1 WO2007097286 A1 WO 2007097286A1 JP 2007052978 W JP2007052978 W JP 2007052978W WO 2007097286 A1 WO2007097286 A1 WO 2007097286A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inflammation
- substance
- group
- functional food
- itching
- Prior art date
Links
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 17
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims abstract description 11
- 235000013376 functional food Nutrition 0.000 title claims abstract description 11
- 230000007803 itching Effects 0.000 title claims abstract description 10
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 9
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 9
- 241000675108 Citrus tangerina Species 0.000 claims description 7
- 241000548268 Citrus deliciosa Species 0.000 claims description 6
- 241000054078 Citrus depressa Species 0.000 claims description 3
- 241000679029 Citrus kinokuni Species 0.000 claims description 3
- 244000175448 Citrus madurensis Species 0.000 claims description 3
- 235000004332 Citrus madurensis Nutrition 0.000 claims description 3
- 235000007438 Citrus mitis Nutrition 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 2
- 230000005722 itchiness Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 3
- 239000000126 substance Substances 0.000 description 25
- 230000001139 anti-pruritic effect Effects 0.000 description 10
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 6
- 201000008937 atopic dermatitis Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000001399 Kallikrein Human genes 0.000 description 5
- 108060005987 Kallikrein Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000003908 antipruritic agent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 241000207199 Citrus Species 0.000 description 3
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 241000675110 Citrus sunki Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960000645 histamine hydrochloride Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a drug for suppressing and / or alleviating itching and inflammation, and a functional food that can enhance the therapeutic effect without side effects when used in combination with an ethical drug.
- This pruritus includes itch that can be suppressed with commercially available antipruritics such as antihistamines such as eczema and urticaria (general hemorrhoids), dermatoses of hemodialysis patients, and senile cutaneous epilepsy.
- antihistamines and steroid preparations such as pruritus and atopic dermatitis, have itch that cannot be controlled (refractory hemorrhoids), but common commercially available antipruritic drugs mainly composed of antihistamines are difficult to treat. If it is used as an internal medicine that can be used by force if it is powerless, it has the disadvantage of causing side effects such as drowsiness (central depression).
- Patent Document 1 Japanese Patent Laid-Open No. 2002-338537
- the present invention has been devised to solve such problems of the prior art, and its main purpose is to safely suppress and alleviate all itch of general and intractable epilepsy. Get The objective is to provide drugs and functional foods that can also suppress and / or alleviate inflammation.
- the present invention provides a drug characterized by containing a highly lipophilic polyalkoxyflavonoid extracted from the squeezing fluid force of the whole fruit of citrus fruits (fruit including the skin).
- the citrus fruits include T. tachibana, C. deliciosa, C. kinokuni, C. eryth rosa, C. tangerina, C. tangerina. ), C.sunki, Citrus depressa, C.tardiva, C.retuculata, C.hanayu, and other fertiles grown in Southeast Asia It is better to select a group strength consisting of citrus calamancy (C. calamondin).
- these drugs should be included in functional foods.
- the substance having an antipruritic action and an anti-inflammatory action according to the present invention is a highly lipophilic polyalkoxyflavonoid contained in the juice of the whole fruit of citrus fruits (fruit including the skin).
- This substance includes T. tac Wbana, C. deliciosa, C. kinokuni, C. erythrosa, C. tangerina, C. tangerina, Sunki, Citrus depressa, C. tardiva, C. retuculata, C. hanayu, and fertility grown in Southeast Asia It is contained in fruits containing citrus peels selected from the group consisting of C. calamondin and can be extracted relatively easily from the juice of all these fruits.
- the highly lipophilic polyalkoxyflavonoids related to the present invention are contained in a large amount in the citrus peel, the residue after squeezing is finely pulverized into fruit juice obtained by pressing or centrifuging the whole fruit.
- the mixture can be extracted and applied by applying this known hydrodynamic purification method.
- Polymethoxylated Flavonoids from the Peels of itrus depressa Yoshiniro imaki et ai. Natural Medicines 54 (6), 351 (200 0)).
- an eluate containing a highly lipophilic polyalkoxyflavonoid (tangerine, nobiletin) can be obtained.
- a powder formulation can be obtained by spray drying or freeze drying the concentrated solution.
- a puppy animal model that induces general pupae and refractory pupae is created using guinea pigs. Specifically, the hair on the right flank of Hartley male guinea pigs (8 weeks old) was shaved on the day before the experiment with a clipper and shaver, and the general acupuncture model was histamine hydrochloride (0.3 mg / ml). In the model, porcine spleen-derived kallikrein (0.05 units in 25 units) was administered intradermally to cause bruising.
- a sprout animal model can be obtained that can similarly determine the antipruritic effect on general hemorrhoids that can be suppressed with conventional antipruritic drugs and refractory epilepsy that cannot be suppressed with conventional antipruritic drugs (The Journal of Tokyo published in 2002) Medical University Vol.60 No.2 123-129 Shellfish "Evalation of antipruritic effect of apple polyphenols usinga new animal model of pruritus.")
- the mottled animal models are divided into two groups with an appropriate number of animals (for example, 12).
- the first group (control group) contains 10% glycerin solution and the second group (test substance application group).
- the cumulative ⁇ behavior time of the control group immediately after histamine development was 25.50 ⁇ 5.11 (second Z120 minutes)
- the group to which the substance of the present invention was applied was 17.08 ⁇ 5.26 (second Z 120 minutes), and showed a significant inhibitory action.
- the cumulative ⁇ behavior time of the control group immediately after the occurrence of kallikrein (refractory ⁇ ) was 52.00 ⁇ 7.08 (second Z120 minutes)
- the group to which the substance of the present invention was applied was 39.33 ⁇ 6.39 (second Z120 minutes), which also showed a significant inhibitory action.
- the substance of the present invention having a sufficient concentration of 1% or more provided sufficient antipruritic action equivalent to that for histamine sputum. It has been demonstrated that
- ICR female mice (5-week-old) are divided into two groups of 12 mice per group, and the first group (control group) contains 0.3% carboxycellulose (CMC) suspension, In group 2 (test substance administration group), a solution of the substance of the present invention in a 0.3% CMC suspension was applied to each individual body weight in an amount equivalent to 100 mg / kg for 1 week. Was continuously administered by oral gavage (inner month ⁇ ). Feeding and water were taken freely. The next day one week after administration, monoclonal anti-DNP IgE ant3 ⁇ 4odies was passively sensitized by administration of 0.5 ml tail vein as an antigenic substance, and the skin reaction was induced by IgE antibody.
- CMC carboxycellulose
- DNFB dinitrofluorobenzene
- acetone-olive oil 4: 1 mixed solution 0.1% DNFB solution was applied to the mouse auricle 1 hour after induction to induce skin inflammation Then, every 1, 4, 24, and 48 hours, the thickness of the pinna (inflammation degree! / ⁇ ) was measured with a dial thickness gauge (Mitutoyo) for each group.
- the bimodal inflammatory responses after 1 and 24 hours of the control group were 6.33 ⁇ 0.41 (X10—2mm), 4.49 ⁇ , respectively.
- the test substance administration groups were 4.87 ⁇ 0.50 (X10—2 mm) and 3.47 ⁇ 0.55 (X10 2 mm), respectively, compared to 0.45 (X10—2 mm).
- type I allergic disease involving immunoglobulin E (IgE antibody) such as rhinitis, hay fever and asthma, house dust such as atopic dermatitis, pollen
- IgE antibody immunoglobulin E
- it is effective to suppress and alleviate the symptoms of type IV allergic diseases caused by various antigenic substances such as inhalation of spores, dietary and food allergens.
- IgE antibody immunoglobulin E
- it has a bimodality of immediate type (after 1 hour) and late type (after 24 hours), but these types of immediate occurrence correspond to histamine occurrence (general defect).
- delayed onset corresponds to kallikrein onset (refractory onset).
- the above-described evaluation test method is a simple method capable of screening for effective substances that simultaneously suppress and alleviate each symptom in a group of type I allergic diseases involving IgE antibodies. If details of this test method are necessary, the application pharmacology Vol. 69 N published on October 1, 2005, Vol. 69 N 0.1 / 2, pages 47-51, “Development of an evaluation method for the effect of improving allergic diseases such as atopic dermatitis. And its application to the development of functional foods.
- the highly lipophilic polyalkoxyflavonoid related to the present invention is used as a pharmaceutical
- an amount of the highly lipophilic polyalkoxyflavonoid effective for prevention or treatment is formulated together with a pharmaceutically acceptable carrier or diluent. Good to be done.
- binders, absorption accelerators, lubricants, emulsifiers, surfactants, antioxidants, preservatives, colorants, flavors, sweeteners, and the like may be added.
- the blending ratio of the highly lipophilic polyalkoxyflavonoid, which is an active ingredient, to the carrier component is in the range of 0.05 to 30.0% by weight, particularly 0.1 to 5.0. A range of weight percent is preferred.
- the dosage form of the pharmaceutical preparation includes a dispersion, a spray, a liquid, a suspension, an ointment, a gel, a paste, a cream, a granule, a fine granule, a tablet, a pill, Capsule and the like can be mentioned, and as its administration route, it is possible to list various administration routes such as application, application, oral, intravenous, intramuscular, subcutaneous, joint cavity, etc. is there.
- usual components to be added to general external preparations for skin may be appropriately added as necessary.
- the dose and frequency of administration of the active ingredient can be appropriately changed according to the disease state, age, sex, administration route and the like.
- the drug containing the highly lipophilic polyalkoxyflavonoid related to the present invention is used as a functional food for suppressing and alleviating itchiness and inflammation and added to all foods and drinks such as confectionery and soft drinks.
- Functional foods consist of natural products containing one or more nutrients and processed products thereof, and are manufactured so as to fully exert physiological functions (tertiary functions) such as regulation of biological functions. (Refer to pages 92 and 93 of July 30, 2003, published by Daiichi Publishing Co., Ltd., Health 'Nutritional Food Advisory' Staff 'Textbook).
- FIG. 1 is a comparison graph of sputum time between a control group and a substance-coated substance (external use) group in histamine development.
- FIG. 2 is a comparison graph of sputum time between a control group and a substance-coated (external use) group in kallikrein onset.
- FIG. 3 is a graph showing a comparison of ear thickness between a control group and a group administered with the substance of the present invention (internal use).
- FIG. 4 is a comparison graph of sputum time between a control group and a group administered with the substance of the present invention (internal use).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07714504.3A EP1987826B1 (en) | 2006-02-22 | 2007-02-19 | Medicine and functional food for controlling or relieving itching and inflammation |
KR1020087020495A KR101430509B1 (ko) | 2006-02-22 | 2007-02-19 | 소양증 및 염증을 억제·완화하기 위한 의약 및 기능성 식품 |
JP2008501707A JP4819869B2 (ja) | 2006-02-22 | 2007-02-19 | 難治性掻痒の痒み並びに炎症を抑制・緩和するための薬剤 |
US12/224,193 US20090304828A1 (en) | 2006-02-22 | 2007-02-19 | Pharmaceutical Composition and Functional Food for Suppressing and Relieving Itching and Inflammation |
CA2643270A CA2643270C (en) | 2006-02-22 | 2007-02-19 | Pharmaceutical composition and functional food for suppressing and relieving itching and inflammation |
AU2007218779A AU2007218779B2 (en) | 2006-02-22 | 2007-02-19 | Pharmaceutical composition and functional food for suppressing and relieving itching and inflammation |
US13/371,085 US8889198B2 (en) | 2006-02-22 | 2012-02-10 | Method for suppressing and relieving itching and inflammation |
US14/517,818 US9017739B2 (en) | 2006-02-22 | 2014-10-18 | Method for suppressing and relieving itching and inflammation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-044801 | 2006-02-22 | ||
JP2006044801 | 2006-02-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/224,193 A-371-Of-International US20090304828A1 (en) | 2006-02-22 | 2007-02-19 | Pharmaceutical Composition and Functional Food for Suppressing and Relieving Itching and Inflammation |
US13/371,085 Division US8889198B2 (en) | 2006-02-22 | 2012-02-10 | Method for suppressing and relieving itching and inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007097286A1 true WO2007097286A1 (ja) | 2007-08-30 |
Family
ID=38437326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/052978 WO2007097286A1 (ja) | 2006-02-22 | 2007-02-19 | 痒み並びに炎症を抑制・緩和するための薬剤及び機能性食品 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20090304828A1 (ja) |
EP (1) | EP1987826B1 (ja) |
JP (1) | JP4819869B2 (ja) |
KR (1) | KR101430509B1 (ja) |
AU (1) | AU2007218779B2 (ja) |
CA (1) | CA2643270C (ja) |
WO (1) | WO2007097286A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010241802A (ja) * | 2009-03-31 | 2010-10-28 | Lvmh Recherche | ミトコンドリアアコニターゼを刺激する美容ケアの方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014103410A1 (ja) * | 2012-12-26 | 2014-07-03 | 森永乳業株式会社 | Igf-1産生促進剤 |
KR101677083B1 (ko) * | 2014-11-10 | 2016-11-17 | 대한민국 | 항염증 활성 조성물 및 이를 포함하는 염증 질환 예방 또는 치료용 약학적 조성물 |
KR101629706B1 (ko) * | 2015-09-08 | 2016-06-13 | (주)셀트리온 | 황사와 미세먼지에 의해 유발된 염증을 완화시키는 천연식물 추출물을 포함하는 조성물 |
CN110354226A (zh) * | 2019-08-23 | 2019-10-22 | 太康海恩药业有限公司 | 止痒组合物及其加工方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07118151A (ja) * | 1993-10-21 | 1995-05-09 | Kureha Chem Ind Co Ltd | アトピー性皮膚炎治療剤 |
JP2001240539A (ja) * | 2000-03-02 | 2001-09-04 | Machida & Machida Shokai:Kk | 血圧上昇または血糖上昇を抑制するための薬剤または機能性食品 |
JP2004091489A (ja) * | 2002-09-02 | 2004-03-25 | Merck Patent Gmbh | 湿疹治療用フラボノイド誘導体 |
JP2005336070A (ja) * | 2004-05-25 | 2005-12-08 | Sanei Gen Ffi Inc | マスト細胞IgEレセプター発現抑制物質、及びそれを含む組成物 |
JP2006348003A (ja) * | 2005-06-20 | 2006-12-28 | Sanei Gen Ffi Inc | マスト細胞IgEレセプター発現抑制剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002338537A (ja) | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | アミド化合物およびその医薬用途 |
JP2003192588A (ja) * | 2001-12-27 | 2003-07-09 | National Agricultural Research Organization | 紫外線誘発プロスタグランジンe2産生抑制剤 |
JP2004083417A (ja) * | 2002-08-22 | 2004-03-18 | National Agriculture & Bio-Oriented Research Organization | 血管新生抑制剤 |
JP2005213178A (ja) * | 2004-01-29 | 2005-08-11 | Maruzen Pharmaceut Co Ltd | TNF−α産生抑制剤、エストロゲン様作用剤及び皮膚外用剤 |
-
2007
- 2007-02-19 US US12/224,193 patent/US20090304828A1/en not_active Abandoned
- 2007-02-19 WO PCT/JP2007/052978 patent/WO2007097286A1/ja active Application Filing
- 2007-02-19 EP EP07714504.3A patent/EP1987826B1/en not_active Expired - Fee Related
- 2007-02-19 KR KR1020087020495A patent/KR101430509B1/ko active IP Right Grant
- 2007-02-19 AU AU2007218779A patent/AU2007218779B2/en not_active Ceased
- 2007-02-19 CA CA2643270A patent/CA2643270C/en not_active Expired - Fee Related
- 2007-02-19 JP JP2008501707A patent/JP4819869B2/ja active Active
-
2012
- 2012-02-10 US US13/371,085 patent/US8889198B2/en active Active
-
2014
- 2014-10-18 US US14/517,818 patent/US9017739B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07118151A (ja) * | 1993-10-21 | 1995-05-09 | Kureha Chem Ind Co Ltd | アトピー性皮膚炎治療剤 |
JP2001240539A (ja) * | 2000-03-02 | 2001-09-04 | Machida & Machida Shokai:Kk | 血圧上昇または血糖上昇を抑制するための薬剤または機能性食品 |
JP2004091489A (ja) * | 2002-09-02 | 2004-03-25 | Merck Patent Gmbh | 湿疹治療用フラボノイド誘導体 |
JP2005336070A (ja) * | 2004-05-25 | 2005-12-08 | Sanei Gen Ffi Inc | マスト細胞IgEレセプター発現抑制物質、及びそれを含む組成物 |
JP2006348003A (ja) * | 2005-06-20 | 2006-12-28 | Sanei Gen Ffi Inc | マスト細胞IgEレセプター発現抑制剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1987826A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010241802A (ja) * | 2009-03-31 | 2010-10-28 | Lvmh Recherche | ミトコンドリアアコニターゼを刺激する美容ケアの方法 |
JP2015212295A (ja) * | 2009-03-31 | 2015-11-26 | エルブイエムエイチ レシェルシェ | ミトコンドリアアコニターゼ活性化剤及びそれを含む美容組成物 |
Also Published As
Publication number | Publication date |
---|---|
KR20090007281A (ko) | 2009-01-16 |
CA2643270C (en) | 2014-07-15 |
EP1987826A1 (en) | 2008-11-05 |
JP4819869B2 (ja) | 2011-11-24 |
KR101430509B1 (ko) | 2014-08-18 |
US20120141615A1 (en) | 2012-06-07 |
CA2643270A1 (en) | 2007-08-30 |
AU2007218779B2 (en) | 2012-12-20 |
EP1987826B1 (en) | 2015-05-27 |
AU2007218779A1 (en) | 2007-08-30 |
US20150037440A1 (en) | 2015-02-05 |
JPWO2007097286A1 (ja) | 2009-07-16 |
US9017739B2 (en) | 2015-04-28 |
US8889198B2 (en) | 2014-11-18 |
US20090304828A1 (en) | 2009-12-10 |
EP1987826A4 (en) | 2011-08-03 |
EP1987826A8 (en) | 2009-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Palatty et al. | Ginger in the prevention of nausea and vomiting: a review | |
JP2009502958A (ja) | ストレスの治療または管理の方法 | |
JP6803849B2 (ja) | インジゴナチュラリス又はインジゴ産生植物の抽出物を用いたアトピー性皮膚炎の処置 | |
US9017739B2 (en) | Method for suppressing and relieving itching and inflammation | |
Frieri | Herbal therapies: what allergist-immunologists should know regarding patient use of complementary and alternative medicine | |
Stengler | The Natural Physician's Healing Therapies: Proven Remedies Medical Doctors Don't Know | |
GB2507254A (en) | Composition for reducing the consumption of food and the absorption of carbohydrate constituents thereof | |
JP2005015414A (ja) | アレルギー性疾患の症状を抑制・緩和するための薬剤または機能性食品 | |
Shirah | The value of Mountain Sidr Honey in treating and controlling chronic constipation: A Prospective comparative study between Ziziphus honey and Lactulose in 1000 Saudi Arabian patients | |
JP4221266B2 (ja) | アレルギー性疾患の症状を抑制・緩和するための薬剤 | |
JP2009263384A (ja) | I型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬 | |
JP2008133292A (ja) | 痒みを抑制するための薬剤 | |
Mehra et al. | Homoeopathic pathogenetic trial of Withania somnifera: A multicentric, double‑blind, randomised, placebo‑controlled trial | |
Karimi et al. | Childhood Asthma Treatment in a 12-year-old Boy according to Iranian Traditional Medicine in Tehran | |
Dharmananda | Rare reactions to a safe herb | |
Shukla | Health is Wealth & Wealth is Pugos Nutrition | |
Willix | The Rejuvenation Solution: Age in Reverse--7 Proven Medical Breakthroughs That Prevent Disease and Make You Feel Years Younger | |
CN103960398B (zh) | 一种含鱼眼草减肥茶及其制备方法 | |
CN104431057B (zh) | 一种含葫芦茶减肥茶及其制备方法 | |
JP2009263385A (ja) | I型アレルギー性疾患の鼻炎の症状を抑制するための内服薬 | |
CN103751440A (zh) | 一种治疗过食羊肉型高脂血症的中药制备方法 | |
JP2007131643A (ja) | アレルギー性疾患の症状を抑制・緩和するための薬剤 | |
JP2007145774A (ja) | 体温調節剤 | |
JP2003321372A (ja) | 抗アレルギー性組成物 | |
CN105770220A (zh) | 一种含有氯沙坦的治疗高血压的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2008501707 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007218779 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3385/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007714504 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2643270 Country of ref document: CA Ref document number: 1020087020495 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007218779 Country of ref document: AU Date of ref document: 20070219 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12224193 Country of ref document: US |